Legislative bodies and regulatory agencies across several U.S. states are actively considering or implementing new frameworks impacting the industrial hemp and hemp-derived cannabinoid product markets. These hemp policy updates in Delaware, Illinois, Nebraska, New Jersey, Pennsylvania (Philadelphia), and Virginia address product classifications, THC limits, and retail regulations, according to a report dated May 27, 2026.
Restrictive Measures on Hemp-Derived Products
Several jurisdictions are proposing legislation that would significantly alter the market for hemp-derived cannabinoid products, primarily through stricter total tetrahydrocannabinol (THC) limits and reclassification.
- Delaware HB 395: This bill, which has advanced out of committee, aims to restructure Delaware’s hemp framework by treating many hemp-derived cannabinoid products as marijuana products. It proposes a total THC content threshold of 0.4 milligrams per container for products that would otherwise be classified as marijuana, a standard that could effectively prohibit 95% of existing hemp products. The legislation also sets a 0.3% total THC limit for industrial hemp and prohibits products containing “counterfeit THC ingredients”—cannabinoids not naturally produced by the cannabis plant or artificially synthesized—if intended for human or animal consumption.
- Illinois HB5784: Introduced as a broad cannabis omnibus bill, HB5784 in Illinois seeks to impose a strict 0.4 milligram per container cap on total THC and other cannabinoids deemed to have similar effects. Products exceeding this threshold would be reclassified, only permitting their sale through licensed cannabis dispensaries. The bill would also exclude many current hemp-derived cannabinoid products from the legal definition of hemp, establish extensive registration and compliance requirements for retailers and manufacturers, and grant broad enforcement authority.
- Pennsylvania (Philadelphia) Bill No. 260163: Philadelphia City Council is considering an ordinance to establish a new regulatory framework for “intoxicating substances,” including hemp-derived cannabinoid products. This bill proposes prohibiting the sale of final hemp-derived cannabinoid products containing more than 0.4 milligrams per container of total tetrahydrocannabinols and similar-effect cannabinoids. Additional provisions include:
- Prohibition of certain cannabinoids not naturally produced by cannabis or synthesized outside the plant.
- Restriction of sales to individuals 21 years of age or older.
- Requirement for retailers to obtain an “Intoxicating Substance Retailer” license for each location.
- Imposition of zoning and location restrictions on retailers.
- Establishment of testing requirements for THC concentration, contaminants, heavy metals, pesticides, solvents, mycotoxins, and microbial impurities.
- Mandatory labeling requirements and civil penalties for violations.
These proposed measures, if enacted, could substantially restrict the existing hemp marketplace in these regions, impacting many federally lawful hemp-derived cannabinoid products currently sold through traditional retail channels.
Regulatory Adjustments and Monitoring
Other states are either refining existing regulations or monitoring potential changes to their hemp frameworks.
- Nebraska Proposed Adulterated Food Product Regulations: The Nebraska Department of Agriculture has issued a Notice of Rulemaking Hearing regarding proposed “Adulterated Food Product Regulations” under the Nebraska Pure Food Act. These regulations would establish standards for determining when food products are considered adulterated or misbranded, potentially deeming products containing tetrahydrocannabinols as such. The notice specifically references products marketed as gummies, drops, and beverages, including certain synthetic THC products. A rulemaking hearing is scheduled for June 18, 2026.
- New Jersey A5051 / S4297: New Jersey, which already maintains a restrictive hemp framework, is considering legislation to revise portions of its existing system. A5051 has passed the House, and companion legislation S4297 has been introduced in the Senate. The legislation would extend certain May 31, 2026, implementation deadlines related to hemp processing and intoxicating hemp beverages until November 13, 2026. It also proposes revisions to permitted container formats for intoxicating hemp beverages, allowing cans with up to 5 milligrams of THC per serving and 10 milligrams per container, and resealable 750 mL bottles with up to 40 servings of 5 milligrams each, or 200 milligrams total THC per bottle. The legislation would also remove certain requirements for intoxicating hemp beverages to be stored behind counters, allowing display in customer-accessible areas under specific monitoring, signage, and age-verification conditions. It would also allow a 10 percent variance in laboratory testing results for cannabinoid concentrations and expand the ability of certain alcohol license holders to sell intoxicating hemp beverages for off-premises consumption. The legislation maintains existing restrictions on many non-beverage hemp-derived cannabinoid products.
Virginia’s Adult-Use Veto and Hemp Implications
Virginia Governor Abigail Spanberger vetoed SB 542/HB 642, legislation that would have established a regulated adult-use marijuana retail marketplace in the Commonwealth. While primarily focused on marijuana regulation, the bill had been observed by hemp and cannabis industry stakeholders due to potential downstream impacts on intoxicating hemp products and future regulatory discussions. Governor Spanberger cited concerns related to public safety, impaired driving, youth access, and broader implementation issues for the veto. The U.S. Hemp Roundtable, represented by General Counsel Jonathan Miller, stated that the organization had asked Governor Spanberger to veto the legislation because it imposed new restrictions on legal hemp products. While the veto did not directly change Virginia’s existing hemp framework, discussions on hemp policy are expected to continue as lawmakers evaluate future approaches to cannabinoid regulation.
These ongoing legislative and regulatory developments underscore the dynamic nature of state-level hemp policy updates and their potential to reshape the market landscape for hemp-derived products across the country.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
